Top 15 most valuable health care and pharmaceutical companies on Egyptian Exchange

Egypt’s healthcare and pharmaceutical stocks are emerging as some of the most resilient plays on the Egyptian Exchange (EGX), backed by a population exceeding 110 million, rising chronic disease treatment demand, and expanding health insurance coverage.

Government support for domestic drug manufacturing and export growth across Africa and the Middle East has further strengthened investor confidence.

As policymakers push for import substitution and export expansion across Africa and the Middle East, listed pharmaceutical manufacturers, distributors, hospitals, and biotech firms are scaling production, deepening research capabilities, and strengthening balance sheets. Investor appetite has followed, lifting valuations across the board.

From generics powerhouse EIPICO to distribution leader Ibnsina Pharma and biotech innovator Minapharm, listed healthcare companies are scaling production, expanding research capabilities, and strengthening balance sheets.

Despite currency pressures, pricing controls, and rising input costs, many players have demonstrated resilience through export growth, product diversification, and operational efficiency. 

Together, the 15 most valuable healthcare and pharmaceutical stocks on the Egyptian bourse represent EGP97.25 billion ($2.07 billion) out of a total market capitalization of EGP3.27 trillion ($69.81 billion), and a sector positioned at the center of Egypt’s long-term economic and social development strategy.

Below are the top 15 companies leading that transformation, as chronicled by Shore Africa

1. Egyptian International Pharmaceuticals (EIPICO)
Market Valuation: EGP14.16 billion ($302.66 million)
One of Egypt’s largest drug manufacturers, EIPICO dominates the generics market with a broad portfolio spanning antibiotics, cardiovascular, and oncology treatments. Its strong export footprint across MENA and Africa supports hard-currency inflows. Backed by consistent production scale and regulatory credibility, EIPICO remains a defensive healthcare stock favored by long-term investors seeking stability and dividend income.

2. Ibnsina Pharma
Market Valuation: EGP12.73 billion ($272.21 million)
Egypt’s leading pharmaceutical distributor, Ibnsina Pharma connects manufacturers to over 50,000 pharmacies nationwide. Its asset-light distribution model and nationwide logistics network make it a backbone of the country’s drug supply chain. Strong revenue growth, efficient working capital management, and scale advantages position it as a structural winner in Egypt’s expanding healthcare ecosystem.

3. Rameda (Tenth Of Ramadan Pharmaceutical Industries)
Market Valuation: EGP7.26 billion($155.19 million)
Rameda has built a fast-growing generics platform targeting high-demand therapeutic areas including gastroenterology and chronic diseases. Known for aggressive brand building and export expansion, the company continues to invest in production capacity. Its growth-oriented strategy and improving margins have strengthened investor confidence amid pricing and currency pressures.

4. Alexandria New Medical Center
Market Valuation: EGP6.55 billion ($140.07 million)
A leading private healthcare provider, Alexandria New Medical Center operates premium hospital facilities serving Egypt’s growing middle and upper classes. Rising demand for quality private healthcare has supported earnings resilience. Its valuation reflects strong patient volumes, expanding service offerings, and steady cash generation in an underpenetrated hospital market.

5. Glaxo Smith Kline
Market Valuation: EGP5.63 billion ($120.36 million)
The local arm of global pharmaceutical giant GSK, the company benefits from multinational backing, premium brands, and regulatory strength. Though operating in a tightly controlled pricing environment, its diversified product portfolio across vaccines and specialty medicines supports stable returns and defensive positioning within the EGX healthcare segment.

6. El-Nile Co. For Pharmaceuticals and Chemical Industries
Market Valuation: EGP5.15 billion ($110.08 million)
A state-affiliated pharmaceutical manufacturer, El-Nile plays a critical role in affordable medicine production. Its scale in essential drugs aligns with government healthcare priorities. Despite pricing constraints, its steady domestic demand base and institutional backing provide revenue visibility and sector stability.

7. Minapharm Pharmaceuticals
Market Valuation: EGP4.25 billion ($90.90 million)
Minapharm stands out for its biotechnology capabilities, focusing on high-value biologics and advanced therapies. Its strategic partnerships and export reach elevate it beyond traditional generics manufacturing. Continued R&D investment positions the company to capture future growth in specialty pharmaceuticals and biosimilars.

8. Alexandria Pharmaceuticals
Market Valuation: EGP3.98 billion ($85.16 million)
Another key domestic producer, Alexandria Pharmaceuticals supplies essential medicines across multiple therapeutic areas. Its large-scale manufacturing footprint supports Egypt’s self-sufficiency agenda. Stable demand fundamentals and a strong presence in public-sector procurement underpin its valuation.

9. Cairo Pharmaceuticals
Market Valuation: EGP3.81 billion ($81.44 million)
Cairo Pharmaceuticals maintains a diversified generics portfolio with solid domestic penetration. Focused on operational efficiency and product expansion, the company benefits from rising chronic disease treatment demand. Its consistent earnings profile makes it a steady performer in the healthcare index.

10. Nozha International Hospital
Market Valuation: EGP2.31 billion ($49.29 million)
Nozha International Hospital reflects growing investor interest in private healthcare infrastructure. Serving urban populations with specialized services, the hospital operator benefits from rising insurance coverage and higher per-capita healthcare spending, supporting stable occupancy and recurring revenues.

11. October Pharma
Market Valuation: EGP2.3 billion ($49.18 million)
October Pharma focuses on branded generics and women’s health products. Its niche specialization and export initiatives support growth beyond Egypt’s borders. Strategic portfolio development and cost management have helped sustain margins in a regulated pricing environment.

12. Premium HealthCare Group
Market Valuation: EGP2.01 billion ($42.94 million)
Operating diagnostic and medical service platforms, Premium HealthCare Group taps into rising demand for outpatient and laboratory services. Its scalable healthcare model and growing patient base align with Egypt’s broader healthcare modernization efforts.

13. Arab Pharmaceuticals
Market Valuation: EGP1.94 billion ($41.56 million)
Arab Pharmaceuticals maintains a strong foothold in essential medicine manufacturing. Its consistent supply to government tenders ensures stable demand, while modernization efforts aim to improve efficiency and expand product lines in competitive therapeutic segments.

14. Medical Packaging Company
Market Valuation: EGP1.07 billion ($22.82 million)
Supplying pharmaceutical packaging solutions, this company plays a vital upstream role in Egypt’s drug manufacturing value chain. As local production expands, demand for compliant, high-quality packaging continues to rise, positioning the company as a strategic industrial beneficiary.

15. Sabaa International Company for Pharmaceutical and Chemical
Market Valuation: EGP902.5 million ($19.29 million)
Sabaa International operates in both pharmaceutical manufacturing and chemical production. While smaller in scale, it benefits from rising domestic drug demand and potential export growth. Strategic expansion could unlock stronger valuation upside over the medium term.